Dimed Distribuidora de Medicamentos (BSP:PNVL3) EBIT: R$302 Mil (TTM As of Mar. 2026)


BSP:PNVL3 Dimed SA Distribuidora de Medicamentos BSP:PNVL3
88 GF Score
Price R$11.34
GF Value R$13.48
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Dimed Distribuidora de Medicamentos EBIT?

Dimed Distribuidora de Medicamentos BSP:PNVL3 +0.35% 88 EBIT is R$302 Mil as of Mar. 2026. GuruFocus rates BSP:PNVL3 with a GF Score™ of 88/100 and a GF Value™ of R$13.48 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Dimed Distribuidora de Medicamentos's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was R$77 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was R$302 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dimed Distribuidora de Medicamentos's annualized ROC % for the quarter that ended in Mar. 2026 was -2.05%. Dimed Distribuidora de Medicamentos's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 14.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dimed Distribuidora de Medicamentos's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.91%.

Dimed Distribuidora de Medicamentos  (BSP:PNVL3) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dimed Distribuidora de Medicamentos's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-59.156 * ( 1 - 10.61% )/( (2572.721 + 2597.551)/ 2 )
=-52.8795484/2585.136
=-2.05 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3830.51 - 827.293 - ( 430.496 - max(0, 1320.67 - 2297.587+430.496))
=2572.721

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3663.514 - 761.96 - ( 304.003 - max(0, 1184.327 - 2145.465+304.003))
=2597.551

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Dimed Distribuidora de Medicamentos's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=308.408/( ( (1335.365 + max(777.262, 0)) + (1324.083 + max(837.146, 0)) )/ 2 )
=308.408/( ( 2112.627 + 2161.229 )/ 2 )
=308.408/2136.928
=14.43 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(574.182 + 1166.554 + 28.492) - (827.293 + 0 + 164.673)
=777.262

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(542.282 + 1183.765 + 27.026) - (761.96 + 0 + 153.967)
=837.146

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dimed Distribuidora de Medicamentos's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=302.307/2771.575
=10.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimed Distribuidora de Medicamentos EBIT Related Terms

Dimed Distribuidora de Medicamentos EBIT Historical Data

* Premium members only.

The historical data trend for Dimed Distribuidora de Medicamentos's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dimed Distribuidora de Medicamentos EBIT Chart

Dimed Distribuidora de Medicamentos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 120.36 148.46 194.16 217.44 279.48

Dimed Distribuidora de Medicamentos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 61.02 57.97 81.87 85.37 77.10

BSP:PNVL3 vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dimed Distribuidora de Medicamentos EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dimed Distribuidora de Medicamentos's EV-to-EBIT falls into.


BSP:PNVL3
88GF Score
Dimed SA Distribuidora de Medicamentos BSP:PNVL3
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dimed Distribuidora de Medicamentos EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$302 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of R$302 Mil mean?
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a EBIT of R$302 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dimed Distribuidora de Medicamentos.
Is Dimed Distribuidora de Medicamentos' EBIT too high?
Dimed Distribuidora de Medicamentos' current EBIT is R$302 Mil. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' EBIT compare to LLY and JNJ?
Dimed Distribuidora de Medicamentos' EBIT of R$302 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dimed Distribuidora de Medicamentos. Dimed Distribuidora de Medicamentos's current EBIT is R$302 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.48, compared to a current price of R$11.34 — trading 15.9% below its estimated fair value. The current EBIT is R$302 Mil. Dimed Distribuidora de Medicamentos' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current EBIT is R$302 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?

Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued. The current stock price of R$11.34 is trading 15.9% below its estimated GF Value™ of R$13.48. GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.

Key valuation signals for BSP:PNVL3:

  • EBIT: R$302 Mil
  • GF Value™: R$13.48 vs. price of R$11.34 (15.9% below fair value)
  • GF Score™: 88/100 with 5 warning signs

No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dimed Distribuidora de Medicamentos Business Description

Address Avenida Industrial Belgraf, 865, Eldorado do Sul, RS, BRA, 92990-000
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
88GF Score

Get the complete analysis for BSP:PNVL3

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$11.34
Price
R$13.48
GF Value